Literature DB >> 31773046

Proton Therapy in the Treatment of Anal Cancer in Pelvic Kidney Transplant Recipients: A Case Series.

David Buchberger1, Paul Kreinbrink1, Jordan Kharofa1.   

Abstract

PURPOSE: The incidence of anal cancer in patients with kidney transplants has increased. The definitive treatment for anal cancer is chemotherapy and intensity-modulated radiation therapy. In kidney transplant recipients, sparing the pelvic kidney in the process of delivering radiation to the anus can be challenging. Intensity-modulated proton therapy (IMPT) has been proposed as an alternative to intensity-modulated radiation therapy for the treatment of anal cancer in this population, given its increased ability to spare organs-at-risk. CASE SERIES: We present 4 cases of patients with transplanted pelvic kidneys who subsequently developed anal cancer and were treated with IMPT from 2017 to 2019.
CONCLUSION: Use of IMPT appears to be an acceptable option for the treatment of anal cancer in patients with a pelvic kidney. ©Copyright 2019 The Author(s).

Entities:  

Keywords:  anal cancer; anal neoplasia; intensity-modulated proton therapy; kidney transplant; pelvic kidney

Year:  2019        PMID： 31773046      PMCID： PMC6871631          DOI： 10.14338/IJPT-19-00067.1

Source DB:  PubMed          Journal:  Int J Part Ther        ISSN： 2331-5180


  26 in total

1.  Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.

Authors: 
Journal:  Lancet       Date:  1996-10-19       Impact factor: 79.321

Review 2.  Anal cancer in renal transplant patients.

Authors:  Heena S Patel; Andrew R J Silver; John M A Northover
Journal:  Int J Colorectal Dis       Date:  2005-08-16       Impact factor: 2.571

3.  Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit.

Authors:  D Collett; L Mumford; N R Banner; J Neuberger; C Watson
Journal:  Am J Transplant       Date:  2010-08       Impact factor: 8.086

4.  Cancer incidence among Canadian kidney transplant recipients.

Authors:  P J Villeneuve; D E Schaubel; S S Fenton; F A Shepherd; Y Jiang; Y Mao
Journal:  Am J Transplant       Date:  2007-02-28       Impact factor: 8.086

5.  Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.

Authors:  M Flam; M John; T F Pajak; N Petrelli; R Myerson; S Doggett; J Quivey; M Rotman; H Kerman; L Coia; K Murray
Journal:  J Clin Oncol       Date:  1996-09       Impact factor: 44.544

6.  Cancer after kidney transplantation in the United States.

Authors:  Bertram L Kasiske; Jon J Snyder; David T Gilbertson; Changchun Wang
Journal:  Am J Transplant       Date:  2004-06       Impact factor: 8.086

Review 7.  Cancer in the transplant recipient.

Authors:  Jeremy R Chapman; Angela C Webster; Germaine Wong
Journal:  Cold Spring Harb Perspect Med       Date:  2013-07-01       Impact factor: 6.915

Review 8.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.

Authors:  Andrew E Grulich; Marina T van Leeuwen; Michael O Falster; Claire M Vajdic
Journal:  Lancet       Date:  2007-07-07       Impact factor: 79.321

9.  Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.

Authors:  Roger D James; Robert Glynne-Jones; Helen M Meadows; David Cunningham; Arthur Sun Myint; Mark P Saunders; Timothy Maughan; Alec McDonald; Sharadah Essapen; Martin Leslie; Stephen Falk; Charles Wilson; Simon Gollins; Rubina Begum; Jonathan Ledermann; Latha Kadalayil; David Sebag-Montefiore
Journal:  Lancet Oncol       Date:  2013-04-09       Impact factor: 41.316

10.  Cancer risk following organ transplantation: a nationwide cohort study in Sweden.

Authors:  J Adami; H Gäbel; B Lindelöf; K Ekström; B Rydh; B Glimelius; A Ekbom; H-O Adami; F Granath
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640
View more
  1 in total

Review 1.  De-Escalation of Therapy for Patients with Early-Stage Squamous Cell Carcinoma of the Anus.

Authors:  Eric Miller; Jose Bazan
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.